E. Egorov | Semantic Scholar

Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials

H. Uusitalo, E. Egorov, K. Kaarniranta, Y. Astakhov, A. Ropo
Medicine
Clinical ophthalmology
15 March 2016

Preservative-free tafluprost significantly decreased the symptoms and signs of ocular surface disease and outrated latanoprost in drop comfort and treatment preference.

View PDF

[Antioxidant agents in neuroprotection treatment of glaucoma].

E. Egorov, A. A. Gvetadze, N. G. Davydova
Medicine, Psychology
Vestnik oftalmologii
2013

Improvement of visual acuity, perimetric, electrofisiological indicies and increased blood flow velocity of central retinal artery were registrated and combined mexidol therapy allows improving results in treatment of patients with POAG.

View on PubMed

Systemic risk factors for developing of primary open-angle glaucoma

View via Publisher

Secondary dry eye syndrome: a modern view

E. Egorov, T. B. Romanova, E. G. Rybakova, J. G. Oganezova
Medicine
2017

View via Publisher

Features of dry eye syndrome treatment

E. Egorov
Medicine
2018

View via Publisher

[Structural and functional changes in the retina of patients with primary open-angle glaucoma and compensated intraocular pressure while undergoing retinoprotective therapy].

E. Egorov, V. Erichev, A. V. Yartsev
Medicine
Vestnik oftalmologii
2019

Systemic use of Retinalamin has significant retinoprotective effect confirmed by the dynamics of morphological and functional parameters in patients with POAG and IOP compensation.

View on PubMed

Mitochondrial morphological changes of trabecular cells in patients with primary open-angle glaucoma

E. Egorov, V. N. Alekseev, I. Gazizova, E. Martynova
Medicine
2016

View via Publisher

[The influence of long-term retinal protective therapy on glaucoma progression according to structural and functional tests].

V. V. Strakhov, E. Egorov, V. Erichev, A. V. Yartsev, S. Petrov, D. A. Dorofeev
Medicine
Vestnik oftalmologii
2020

Regular treatment with retinalamin arrests the development of glaucomatous optic neuropathy and longer-term research is required to study its influence on the visual function and the quality of life.

View on PubMed

I. Koroleva, E. Egorov
Medicine
2018

The task of the ophthalmologist will be the combined prescription of drugs with clinically proven antioxidant and metabolic effects that slow down the development of cataracts, for example, Oftan® Catachrom eye drops.

View PDF

Retinalamin for various ophthalmic disorders: clinical experience

E. Egorov
Medicine
2017

View via Publisher